SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test

Neuropsychopharmacology

Volumn 32, Issue 10, 2007, Pages 2163-2172

  Starr, Kathryn R ^a   Price, Gary W ^a   Watson, Jeannette M ^a   Atkinson, Peter J ^a   Arban, Roberto ^a   Melotto, Sergio ^a   Dawson, Lee A ^a   Hagan, Jim J ^a   Upton, Neil ^a   Duxon, Mark S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT (serotonin); Depression; Marmoset; Rat; Threat test; Vocalization

Indexed keywords

6 [[1 [2 [(2 METHYL 5 QUINOLINYL)OXY]ETHYL] 4 PIPERIDINYL]METHYL] 2H 1,4 BENZOXAZIN 3(4H) 1; AUTORECEPTOR; FLUOXETINE; PAROXETINE; SB 649915 B; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY POSTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; LATENT PERIOD; LOCOMOTION; MALE; MATERNAL DEPRIVATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RAT; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE; TRANQUILIZING ACTIVITY; VOCALIZATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; BENZOXAZINES; BRAIN; CALLITHRIX; DRUG SYNERGISM; MALE; MOTOR ACTIVITY; PAROXETINE; PIPERIDINES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SOCIAL BEHAVIOR; VOCALIZATION, ANIMAL;

EID: 34447333181     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301341     Document Type: Article

References (85)

1. Artigas F (1993). 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 14: 262.
2. Artigas F, Perez V, Alvarez E (1994). Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 48-51.
3. 1A receptor antagonists with potent 5-HT reuptake inhibitory activity. Bioorg Med Chem Lett 15: 737-741.
4. Ballesteros J, Callado LF (2004). Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled studies. J Affect Disord 79: 137-147.
5. Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA et al (1999). The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 45: 1170-1177.
6. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS (1997). Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154: 37-43.
7. Berton O, Durand M, Aguerre S, Mormede P, Chaouloff F (1999). Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain. Neuroscience 92: 327-341.
8. Blier P, Bergeron R (1995). Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15: 217-222.
9. Blier P, Bouchard C (1994). Modulation of 5-HT release in the guinea-pig brain following long term administration of antidepressant drugs. Br J Pharmacol 113: 485-495.
10. Blier P, de Montigny C, Chaput Y (1987). Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 7: 24S-35S.
11. Bordet R, Thomas P, Dupuis B (1998). Effect of pindolol with selected antidepressant drugs in the treatment of major depression: intermediate analysis of a double blind, placebo-controlled trial. Am J Psychiatry 155: 1346-1351.
12. Borsini F, Podhorna J, Marazziti D (2002). Do animal models of anxiety predicit anxiolytic-like effects of anti-depressants? Psychopharmacology 163: 121-141.
13. Boulenguez P, Rawlins JN, Chauveau J, Joseph MH, Mitchell SN, Gray JA (1996). Modulation of dopamine release in the nucleus accumbens by 5-HT1B agonists: involvement of the hippocampo-accumbens pathway. Neuropharmacology 35: 1521-1529.
14. 1A receptor antagonist, WAY 100, 635, in the rat. Neuropharmacology 39: 1222-1236.
15. Consolo S, Arnaboldi S, Ramponi S, Nannini L, Ladinsky H, Baldi G (1996). Endogenous serotonin facilitates in vivo acetylcholine release in rat frontal cortex through 5-HT 1B receptors. J Pharmacol Exp Ther 277: 823-830.
16. Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ (1988a). Zaclopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol 40: 302-305.
17. Costall B, Domeney AM, Gerrard PA, Naylor RJ (1988b). A primate model for the assessment of anxiolytic drug action. Br J Pharmacol 95(suppl): 670P.
18. 1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. Eur J Pharmacol 345: 41-46.
19. 1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (±) pindolol. Neuropharmacology 39: 1044-1052.
20. Dawson LA, Nguyen HQ, Smith DL, Schechter LE (2002). Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J Psychopharmacol 16: 145-152.
21. Draper NR, Smith H (1966). Applied Regression Analysis. John Wiley and Sons: New York, NY.
22. 1A receptors. Neurochem Res 21: 557-562.
23. Duman RS (2004). Depression: a case of neuronal life and death? Biol Psychiatry 56: 140-145.
24. Duxon MS, Starr KR, Upton N (2000). Latency to paroxetine-induced anxiolysis in the rat is reduced by co-adminstration of the 5-HT1A receptor antagonist WAY100635. Br J Pharmacol 130: 1713-1719.
25. File SE (1980). The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2: 219-238.
26. File SE, Hyde JR (1978). Can social interaction be used to measure anxiety? Br J Pharmacol 62: 19-24.
27. File SE, Hyde JR (1979). A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants. Pharmacol Biochem Behav 11: 65-69.
28. Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE et al (1996). Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73: 337-353.
29. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y et al (1995). A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281: 81-88.
30. Gardner CR (1985). Distress vocalization in rat pups: a simple screening method for anxiolytic drugs. J Pharmacol Methods 14: 181-187.
31. Gartside SE, Umbers V, Hajos M, Sharp T (1995). Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115: 1064-1070.
32. Gobert A, Dekeyne A, Millan MJ (2000). The ability of WAY100, 635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224, 289, but not BRL15572. Neuropharmacology 39: 1608-1616.
33. Gobert A, Rivet J-M, Cistarelli L, Millan MJ (1997). Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY100, 635 and GR 127, 935. J Neurochem 68: 1159-1163.
34. Gould E (1999). Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 21: 46S-51S.
35. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995). Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120: 57-66.
36. Griebel G, Moreau JL, Jenck F, Misslin R, Martin JR (1994). Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113: 463-470.
37. Hajos-Korcsok E, McQuade R, Sharp T (1999). Influence of 5-HT1A receptors on central noradrenergic activity: microdialysis studies using (+/-)-MDL 73005EF and its enantiomers. Neuropharmacology 38: 299-306.
38. 1A receptor regulation. Neuropsychopharmacology 4: 131-144.
39. Hervas I, Vilaro MT, Romero L, Scorza CM, Mengod G, Artigas F (2001). Desensitisation of 5-HT1A autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635. Neuropsychopharmacology 24: 11-20.
40. Hjorth S (1996). Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur J Pharmacol 303: 183-186.
41. Hjorth S, Auerbach SB (1996). 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav Brain Res 73: 281-283.
42. Hjorth S, Suchowski CS, Galloway MP (1995). Evidence for 5-HT autoreceptor-mediated, nerve impulse-dependent, control of 5-HT synthesis in the rat brain. Synapse 19: 170-176.
43. 1A (auto) receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology 36: 461-465.
44. Hollander E, Decaria C, Gully R, Nitescu A, Suclow RF, Gorman JM et al (1991). Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 36: 1-17.
45. Hoyer D, Middlemiss DN (1989). The pharmacology of the terminal 5-HT autoreceptors in mammalian brain: evidence for species differences. Trends Pharmacol Sci 10: 130-132.
46. 1A/B receptor/5-HT transport inhibitor SB-649915-B. Psychopharmacology (In press on-line).
47. Iyer RN, Bradberry CW (1996). Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 277: 40-47.
48. 2C/2B receptor function. Neuropharmacology 23: 1581-1588.
49. Kennett GA, Lightowler S, Trail B, Bright F, Bromidge S (2000). Effects of RO 60 0175, a 5-HT(2C) receptor agonist, in three animal models of anxiety. Eur J Pharmacol 387: 197-204.
50. Kennett GA, Whitton P, Shah K, Curzon G (1989). Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 164: 445-454.
51. 2C receptor antagonist. Neuropharmacology 36: 609-620.
52. Koyama T, Nakajima Y, Fujii T, Kawashima K (1999). Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAYx3702 in freely moving rats. Neurosci Lett 265: 33-36.
53. 1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmiedebergs Arch Pharmacol 352: 141-148.
54. Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF (1994). Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49: 281-285.
55. Maes M, Libbrecht I, Van Hunsel F, Campens D, Meltzer HY (1999). Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19: 177-182.
56. Maj J, Bijak M, Dziedzicka M, Rogoz R, Rogoz Z, Skuza G et al (1996). The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology 127: 73-82.
57. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104-9110.
58. Marcoli M, Maura G, Munari C, Ruelle A, Raiteri M (1999). Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions. Br J Pharmacol 126: 607-612.
59. McAskill R, Mir S, Taylor D (1998). Pindolol augmentation of antidepressant therapy. B J Psychiatry 173: 203-208.
60. Mongeau R, Blier P, De Montigny C (1997). The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Rev 23: 145-195.
61. Nakai K, Fujii T, Fujimoto K, Suzuki T, Kawashima K (1998). Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis. Neurosci Res 31: 23-29.
62. 1B autoreceptors: regional differences and effects of WAY-100635. Eur J Pharmacol 486: 25-30.
63. 1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum. J Neural Transm 103: 541-554.
64. Nutt DJ (2005). Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 10: 49-56.
65. Olivier B, Molewijk HE, Van Der Heydden JA, Van Oorschot R, Ronken E, Mos J et al (1998). Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Neurosci Biobehav Rev 23: 215-227.
66. Quested DJ, Sargent PA, Cowen PJ (1997). SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology 133: 305-308.
67. Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ et al (2001). Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 158: 2080-2082.
68. 1A receptor antagonist administration decreases cell proliferation in the dentate gyrus. Brain Res 955: 264-267.
69. 1A or 5-HT re-uptake site blockade. Neuropharmacology 38: 1409-1419.
70. Rollema H, Clarke T, Sprouse JS, Schultz DW (1996). Combined administration of a 5-HT1D antagonist and 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea-pig hypothalamus in vivo. J Neurochem 67: 2204-2207.
71. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15: 349-360.
72. Romero L, Hervas I, Artigas F (1996b). The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in the rat brain. Neurosci Lett 219: 123-126.
73. 1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer's disease. Curr Pharmaceut Des 8: 139-145.
74. 1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue. Eur J Pharmacol 536: 54-61.
75. Segrave R, Nathan PJ (2005). Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol Clin Exp 20: 163-174.
76. 1B autoreceptors induced by fluoxetine. Naunyn-Schmiedebergs Arch Pharmacol 370: 84-90.
77. Sharp T, Umbers V, Gartside SE (1997). Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol 121: 941-946.
78. Stein MB, Sareen J, Hami S, Chao J (2001). Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158: 1725-1727.
79. Thomas DR, Nelson DR, Johnson AM (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93: 193-200.
80. To CT, Anheuer ZE, Bagdy G (1999). Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety. Neuroreport 10: 553-555.
81. To CT, Bagdy G (1999). Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology 38: 279-282.
82. Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA et al (2001). SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41: 186-199.
83. Yamauchi M, Tatebayashi T, Nagase K, Kojima M, Imanishi T (2004). Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol Biochem Behav 78: 683-689.
84. Zanardi R, Artigas F, Franchini l, Sforzini L, Gasperini M, Smeraldi E et al (1997). How long should pindolol be associated with paroxetine to improve anti-depreassant response? J Clin Psychopharmacol 17: 446-450.
85. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL (1988). Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry 45: 167-172.